Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Peripheral neuropathy in ART-experienced patients: prevalence and risk factors.

Chen H, Clifford DB, Deng L, Wu K, Lee AJ, Bosch RJ, Riddler SA, Ellis RJ, Evans SR.

J Neurovirol. 2013 Dec;19(6):557-64. doi: 10.1007/s13365-013-0216-4. Epub 2013 Dec 3.

2.

Peripheral neuropathy in HIV: prevalence and risk factors.

Evans SR, Ellis RJ, Chen H, Yeh TM, Lee AJ, Schifitto G, Wu K, Bosch RJ, McArthur JC, Simpson DM, Clifford DB.

AIDS. 2011 Apr 24;25(7):919-28. doi: 10.1097/QAD.0b013e328345889d.

3.

Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen.

Lee AJ, Bosch RJ, Evans SR, Wu K, Harrison T, Grant P, Clifford DB.

J Neurovirol. 2015 Apr;21(2):210-8. doi: 10.1007/s13365-015-0327-1. Epub 2015 Feb 13.

4.

HIV peripheral neuropathy progression: protection with glucose-lowering drugs?

Evans SR, Lee AJ, Ellis RJ, Chen H, Wu K, Bosch RJ, Clifford DB.

J Neurovirol. 2012 Oct;18(5):428-33. doi: 10.1007/s13365-012-0119-9. Epub 2012 Jul 18.

5.

Prevalence of peripheral neuropathy in antiretroviral therapy naïve HIV-positive patients and the impact on treatment outcomes--a retrospective study from a large urban cohort in Johannesburg, South Africa.

Evans D, Takuva S, Rassool M, Firnhaber C, Maskew M.

J Neurovirol. 2012 Jun;18(3):162-71. doi: 10.1007/s13365-012-0093-2. Epub 2012 Apr 20.

PMID:
22528477
6.

Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort.

Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD; HIV Outpatient Study Investigators.

Clin Infect Dis. 2005 Jan 1;40(1):148-57. Epub 2004 Dec 6.

7.

Sex differences in the incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapy.

Mehta SA, Ahmed A, Laverty M, Holzman RS, Valentine F, Sivapalasingam S.

Clin Infect Dis. 2011 Sep;53(5):490-6. doi: 10.1093/cid/cir432.

8.

Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy.

Banerjee S, McCutchan JA, Ances BM, Deutsch R, Riggs PK, Way L, Ellis RJ.

AIDS. 2011 Jan 14;25(2):F1-6. doi: 10.1097/QAD.0b013e328341dd68.

9.

Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study.

Ellis RJ, Rosario D, Clifford DB, McArthur JC, Simpson D, Alexander T, Gelman BB, Vaida F, Collier A, Marra CM, Ances B, Atkinson JH, Dworkin RH, Morgello S, Grant I; CHARTER Study Group.

Arch Neurol. 2010 May;67(5):552-8. doi: 10.1001/archneurol.2010.76.

10.

Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211.

Yeh TM, Evans SR, Gulick RM, Clifford DB.

HIV Clin Trials. 2010 Jan-Feb;11(1):51-8. doi: 10.1310/hct1101-51.

11.

Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation.

Wang SX, Ho EL, Grill M, Lee E, Peterson J, Robertson K, Fuchs D, Sinclair E, Price RW, Spudich S.

J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):303-10. doi: 10.1097/QAI.0000000000000167.

12.

HIV neuropathy in pre-HAART patients and it's correlation with risk factors in Central India.

Dubey TN, Raghuvanshi SS, Sharma H, Saxena R.

Neurol India. 2013 Sep-Oct;61(5):478-80. doi: 10.4103/0028-3886.121912.

13.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
14.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
15.

Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial.

Arenas-Pinto A, Thompson J, Musoro G, Musana H, Lugemwa A, Kambugu A, Mweemba A, Atwongyeire D, Thomason MJ, Walker AS, Paton NI; EARNEST Trial Team.

J Neurovirol. 2016 Feb;22(1):104-13. doi: 10.1007/s13365-015-0374-7. Epub 2015 Aug 25.

PMID:
26323809
16.

[Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2012 Jun;30(6):e1-89. doi: 10.1016/j.eimc.2012.03.006. Epub 2012 May 23. Spanish.

PMID:
22633764
17.

Implementation of a validated peripheral neuropathy screening tool in patients receiving antiretroviral therapy in Mombasa, Kenya.

Mehta SA, Ahmed A, Kariuki BW, Said S, Omasete F, Mendillo M, Laverty M, Holzman R, Valentine F, Sivapalasingam S.

Am J Trop Med Hyg. 2010 Sep;83(3):565-70. doi: 10.4269/ajtmh.2010.09-0629.

18.

The vulnerability of men to virologic failure during antiretroviral therapy in a public routine clinic in Burkina Faso.

Penot P, Héma A, Bado G, Kaboré F, Soré I, Sombié D, Traoré JR, Guiard-Schmid JB, Fontanet A, Slama L, Bruno Sawadogo A, Laurent C.

J Int AIDS Soc. 2014 Jan 15;17:18646. doi: 10.7448/IAS.17.1.18646. eCollection 2014.

19.
20.

Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.

Wit FW, Kesselring AM, Gras L, Richter C, van der Ende ME, Brinkman K, Lange JM, de Wolf F, Reiss P.

Clin Infect Dis. 2008 Mar 15;46(6):933-40. doi: 10.1086/528861.

Items per page

Supplemental Content

Write to the Help Desk